Researchers develop mouse genetic blueprint

Tuesday, 17 September 2013

Islamabad, Sep 18 (Newswire): Researchers have developed a valuable mouse genetic blueprint that will accelerate future research and understanding of human genetics.

The international team, led by researchers at the Wellcome Trust Sanger Institute and the University of Oxford, explains in two papers published in Nature how they decoded and compared the genome sequence of 17 mouse strains.

In creating this unique resource, the biggest catalogue for any vertebrate model organism, the team found an astonishing 56.7 million unique sites of variation (known as SNPs) between the strains, in addition to other more complex differences. Among these they identified sequence differences associated with over 700 biological differences, including markers for diseases such as diabetes and heart disease, so linking genes with medically important individual differences.

The catalogue, which was funded principally by the Medical Research Council and the Wellcome Trust, can be used by researchers to understand the genetic basis of individual variation, and to ask fundamental questions about how genes function and make us more or less likely to have particular diseases.

Inbred strains of mice are invaluable sources of genetic information. Every animal within each inbred strain is essentially genetically identical, but each strain is different from the others both in their genes and across a huge range of medically and biologically important characteristics.

"We are living in an era where we have thousands of human genomes at our finger tips," says Dr Adams, from the Wellcome Trust Sanger Institute, who led the project. "The mouse, and the genome sequences we have generated, will play a critical role in understanding of how genetic variation contributes to disease and will lead us towards new therapies."

As a direct result of the project, researchers will place less reliance on breeding mice to find mutations; using this resource they will be able to find mutations much more quickly by the click of a digital mouse to search for the data on their computer.
These strains of mice are used in every corner of biology to further our understanding of human disease, and there is much more to discover. With the variants to hand, the challenge moves to understanding the biological consequences.

"In some cases it has taken 40 years -- an entire working life -- to pin down a gene in a mouse model that is associated with a human disease, looking for the cause," explains Dr Thomas Keane, who was first author on one of the papers. "Now with our catalogue of variants the analysis of these mice is breathtakingly fast and can be completed in the time it takes to make a cup of coffee.

"We now know where all the variants are, so the questions today are what do they do, and can we explain the phenotypic differences between different strains of mice?"

Crucially, the resource will reduce the amount of mouse breeding and testing needed to identify genes and mutations, reducing the numbers of mice required for each study. The initial discovery can be made computationally. The extensive catalogue will be invaluable for associating variation in a trait with changes to DNA -- the biologist's journey from phenotype to genotype.

Using the sequence of the 17 mouse genomes, the team looked for variants associated with quantitative trait loci (QTLs) implicating differences in the sequence between strains as being associated with the phenotypes that distinguish them.

"This study is a first step in a long path that moves from understanding what the genome is, to what it does," says Professor Jonathan Flint, from the Wellcome Trust Centre for Human Genetics, who co-led the study.

"The biological differences across the inbred strains of mice model variation between individual humans," says Professor Ian Jackson, joint head of Medical and Development Genetics at the Medical Research Council's Human Genetics Unit. "This resource, made possible through huge recent advances in sequencing technology, is transforming our understanding of how DNA sequence variation relates to gene function, and ultimately its association with biology and human health."

The project will be extended by sequencing further mouse strains, defining the genetic changes in mouse cancers and investigating the effect of variants on gene function.

The blueprint, coupled with today's speedier sequencing, enables researchers to probe deeper to find mutations affecting gene function at a much faster rate. It also opens the doorway to the possibility of sequencing much larger numbers of mice, with plans to extend the project to hundreds of mouse strains, a feat that only a few years ago would have seemed impossible.
Continue Reading | comments

Newly discovered protein discovered may suppress breast cancer growth

Islamabad, Sep 18 (Newswire): Research led by Dr. Suresh Alahari, the Fred Brazda Professor of Biochemistry and Molecular Biology at LSU Health Sciences Center New Orleans and its Stanley S. Scott Cancer Center, has found that a protein discovered by his laboratory can inhibit the growth of breast cancer cells.

Building upon Dr. Alahari's earlier discovery of nischarin, a novel protein that regulates breast cancer cell migration and movement, this current study examines the presence and levels of nischarin in breast cancer tumor tissue from 300 women as well as normal breast tissue samples. The researchers also generated derivatives of human metastatic breast cancer cells to test by manipulating the protein in a mouse model.

"We found that normal human breast tissue samples had statistically significantly higher levels of nischarin compared with tumor tissue samples," notes Dr. Alahari, "and tumors grew significantly faster in the cells where we blocked the production of nischarin. Tumor growth and metastasis were also reduced in the samples where we manipulated the overproduction of nischarin. Our research shows that nischarin can function as a tumor suppressor of breast cancer, inhibiting breast cancer progression."

The research team also describes the regulation of nischarin and reports the genetic mechanism by which this protein suppressed breast tumor growth, information that could be used to target new treatment approaches.

Excluding skin cancer, breast cancer is the most common type of cancer among women in the United States. The National Cancer Institute estimates 230,480 new cases among American females this year, and 2,140 among men in the US, with 39,520 deaths in women and 450 deaths in men.

Risk factors include aging, weight gain, combined hormone therapy, physical inactivity, and consumption of one or more alcoholic beverages per day. A family history increases risk, as does never having had children or having a first child after age 30.

Mammography can often detect breast cancer at an early stage when treatment options are greatest and a cure is possible.

"Next steps include determining whether nischarin controls some of its tumor suppressor roles through regulation of the pathways we reported in this paper," concludes Dr. Alahari, "and these studies are already underway."

The LSUHSC research team also included Dr. Robin McGoey, Associate Professor of Pathology. as well as postdoctoral fellows, Drs. Somesh Baranwal, Yanfang Wang, Rajamani Rathinam, and Lianjin Jin. Researchers from Duke University and Memorial Sloan Kettering Cancer Center also contributed.
Continue Reading | comments

Copper reduces infection risk by more than 40%


Islamabad, Sep 18 (Newswire): Professor Bill Keevil, Head of the Microbiology Group and Director of the Environmental Healthcare Unit at the University of Southampton, has presented research into the mechanism by which copper exerts its antimicrobial effect on antibiotic-resistant organisms at the World Health Organization's first International Conference on Prevention and Infection Control (ICPIC).

'New Insights into the Antimicrobial Mechanisms of Copper Touch Surfaces' observes the survival of pathogens on conventional hospital touch surfaces contributes to increasing incidence and spread of antibiotic resistance and infections. Keevil proposes antimicrobial copper surfaces as one way to address this, since they achieve a rapid kill of significant bacterial, viral and fungal pathogens.

He reported studies on dry surfaces with a range of pathogens, concluding that: "Copper's rapid destruction of pathogens could prevent mutational resistance developing and also help reduce the spread of antibiotic resistance genes to receptive and potentially more virulent organisms, as well as genes responsible for virulence. Additionally, copper touch surfaces could have a key role in preventing the transmission of healthcare-associated infections.

Extensive laboratory tests have demonstrated copper's antimicrobial efficacy against key organisms responsible for these infections, and clinical trials around the world are now reporting on its efficacy in busy, real-world environments."

The latest trial -- conducted in intensive care units at three facilities in the United States -- has shown that the use of antimicrobial copper surfaces in intensive care unit rooms resulted in a 40.4% reduction in the risk of acquiring a hospital infection.

The study, funded by the US Department of Defense, was designed to determine the efficacy of antimicrobial copper in reducing the level of pathogens in hospital rooms, and whether such a reduction would translate into a lower rate of infection.

Researchers at the three hospitals involved in the trial -- Memorial Sloan Kettering Cancer Center in New York, the Medical University of South Carolina (MUSC) and the Ralph H. Johnson VA Medical Center, both in Charleston, South Carolina -- replaced commonly-touched items such as bed rails, overbed tray tables, nurse call buttons and IV poles with antimicrobial copper versions.

Data presented by trial leader Dr Michael Schmidt, Professor and Vice Chairman of Microbiology and Immunology at MUSC, at ICPIC, demonstrated a 97% reduction in surface pathogens in rooms with copper surfaces, the same level achieved by "terminal" cleaning: the regimen conducted after each patient vacates a room.
Dr Schmidt said of the results: "Bacteria present on ICU room surfaces are probably responsible for 35-80% of patient infections, demonstrating how critical it is to keep hospitals clean. The copper objects used in the clinical trial supplemented cleaning protocols, lowered microbial levels, and resulted in a statistically significant reduction in the number of infections contracted by patients treated in those rooms."
Continue Reading | comments
 
Copyright © 2011. Newswire . All Rights Reserved
Company Info | Contact Us | Privacy policy | Term of use | Widget | Advertise with Us | Site map
Template Modify by Creating Website. Inpire by Darkmatter Rockettheme Proudly powered by Blogger